×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
OTCMKTS:PMCB

PharmaCyte Biotech Stock Forecast, Price & News

$2.24
0.00 (0.00%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.23
$2.31
50-Day Range
$2.01
$2.33
52-Week Range
$1.79
$21.00
Volume
120,426 shs
Average Volume
210,679 shs
Market Capitalization
$46.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PharmaCyte Biotech MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.58 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PharmaCyte Biotech logo

About PharmaCyte Biotech (OTCMKTS:PMCB) Stock

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.

PMCB Stock News Headlines

How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
PharmaCyte Biotech Shares Reverse Course, Drop 8%
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
PharmaCyte Biotech reports Q3 results
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PMCB
Employees
4
Year Founded
N/A

Company Calendar

Last Earnings
12/15/2021
Today
7/03/2022
Fiscal Year End
4/30/2023

Profitability

Net Income
$-3.55 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$46.41 million
Optionable
Not Optionable
Beta
-0.02














PharmaCyte Biotech Frequently Asked Questions

Should I buy or sell PharmaCyte Biotech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PharmaCyte Biotech in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PharmaCyte Biotech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PMCB, but not buy additional shares or sell existing shares.
View analyst ratings for PharmaCyte Biotech
or view top-rated stocks.

How has PharmaCyte Biotech's stock price performed in 2022?

PharmaCyte Biotech's stock was trading at $2.50 at the start of the year. Since then, PMCB stock has decreased by 10.4% and is now trading at $2.24.
View the best growth stocks for 2022 here
.

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) released its quarterly earnings results on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01.
View PharmaCyte Biotech's earnings history
.

Who are PharmaCyte Biotech's key executives?

PharmaCyte Biotech's management team includes the following people:
  • Mr. Kenneth L. Waggoner Esq., Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 74, Pay $433.33k)
  • Mr. Carlos A. Trujillo CPA, CPA, CFO & Director (Age 64, Pay $300k)
  • Dr. Gerald W. Crabtree Ph.D., Chief Scientific Officer & Director (Age 81, Pay $94.33k)
  • Dr. Jose L. Iglesias M.D., Consulting Chief Medical Officer (Age 65)
  • Dr. Hans-Peter Hammes, Member of Medical & Scientific Advisory Board and Consultant

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX).

What is PharmaCyte Biotech's stock symbol?

PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PharmaCyte Biotech's stock price today?

One share of PMCB stock can currently be purchased for approximately $2.24.

How much money does PharmaCyte Biotech make?

PharmaCyte Biotech (OTCMKTS:PMCB) has a market capitalization of $46.41 million.

How many employees does PharmaCyte Biotech have?

PharmaCyte Biotech employs 4 workers across the globe.

How can I contact PharmaCyte Biotech?

PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The official website for PharmaCyte Biotech is www.pharmacyte.com. The company can be reached via phone at (917) 595-2850, via email at info@pharmacyte.com, or via fax at 917-595-2851.

This page (OTCMKTS:PMCB) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.